Determination of cathepsin S abundance and activity in human plasma and implications for clinical investigation

Analytical Biochemistry

Volumn 430, Issue 2, 2012, Pages 130-137

  Cox, Jennifer M ^a   Troutt, Jason S ^a   Knierman, Michael D ^a   Siegel, Robert W ^a   Qian, Yue Wei ^a   Ackermann, Bradley L ^a   Konrad, Robert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cathepsin S; Cystatin C; ELISA; Enzyme activity; LC MS MS

Indexed keywords

LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

ABDOMINAL AORTIC ANEURYSMS; CATHEPSIN S; CLINICAL INVESTIGATION; CYSTATIN C; ELISA; ENZYME LINKED IMMUNOSORBENT ASSAY; LC-MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ASSAYS;

ENZYME ACTIVITY;

CATHEPSIN S; CYSTATIN C;

ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

EID: 84866496751     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2012.08.011     Document Type: Article

References (26)

1. W. Liu, and D.M. Spero Cysteine protease cathepsin S as a key step in antigen presentation Drug News Perspect. 17 2004 357 363
2. S. Gupta, R.K. Singh, S. Dastidar, and A. Ray Cysteine cathepsin S as an immunomodulatory target: present and future trends Expert Opin. Ther. Targets 12 2008 291 299
3. D. Small, R. Burden, and C. Scott The emerging relevance of the cysteine protease cathepsin S in disease Clin. Rev. Bone Miner. Metab. 9 2011 122 132
4. J. Liu, G.K. Sukhova, J.-S. Sun, W.-H. Xu, P. Libby, and G.-P. Shi Lysosomal cysteine proteases in atherosclerosis Arterioscler. Thromb. Vasc. Biol. 24 2004 1359 1366
5. S.P.M. Lutgens, K.B.J.M. Cleutjens, M.J.A.P. Daemen, and S. Heeneman Cathepsin cysteine proteases in cardiovascular disease FASEB J. 21 2007 3029 3041
6. J.-C. Lafarge, N. Naour, K. Clément, and M. Guerre-Millo Cathepsins and cystatin C in atherosclerosis and obesity Biochimie 92 2010 1580 1586
7. G.K. Sukhova, and G.-P. Shi Do cathepsins play a role in abdominal aortic aneurysm pathogenesis? Ann. NY Acad. Sci. 1085 2006 161 169
8. G.K. Sukhova, G.P. Shi, D.I. Simon, H.A. Chapman, and P. Libby Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells J. Clin. Invest. 102 1998 576 583
9. J. Liu, L. Ma, J. Yang, A. Ren, Z. Sun, G. Yan, J. Sun, H. Fu, W. Xu, C. Hu, and G.-P. Shi Increased serum cathepsin S in patients with atherosclerosis and diabetes Atherosclerosis 186 2006 411 419
10. G.-P. Shi, G.K. Sukhova, A. Grubb, A. Ducharme, L.H. Rhode, R.T. Lee, P.M. Ridker, P. Libby, and H.A. Chapman Cystatin C deficiency in human atherosclerosis and aortic aneurysms J. Clin. Invest. 104 1999 1191 1197
11. G. Fei-Fei, L. Shu-Zheng, C. Yun-Dai, Z. Yu-Jie, S. Xian-Tao, J. Ze-Ning, and L. Hong Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound Chin. Med. J. 122 2009 2820 2826
12. J.S. Lindholt, E.J. Erlandsen, and E.W. Henneberg Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms Br. J. Surg. 88 2001 1472 1475
13. C. Palermo, and J.A. Joyce Cysteine cathepsin proteases as pharmacological targets in cancer Trends Pharmacol. Sci. 29 2008 22 28
14. W.S.W. Chang, H.R. Wu, C.T. Yeh, C.W. Wu, and J.Y. Chang Lysosomal cysteine proteinase cathepsin S as a potential target for anticancer therapy J. Cancer Mol. 3 2007 5 14
15. S. Taleb, and K. Clément Emerging role of cathepsin S in obesity and its associated diseases Clin. Chem. Lab. Med. 45 2007 328 332
16. J.-C. Lafarge, K. Clément, and M. Guerre-Millo Cathepsins S, L, and K and their pathophysiological relevance in obesity Clin. Rev. Bone Miner. Metab. 9 2011 133 137
17. C.S. Mason, M.B.A.C. Lamers, I.M.J. Henderson, T. Monk, and D.H. Williams Baculoviral expression and characterization of rodent cathepsin S Protein Expr. Purif. 23 2001 45 54
18. R.L. Rich, and D.G. Myszka Higher-throughput, label-free, real-time molecular interaction analysis Anal. Biochem. 361 2007 1 6
19. 2, a matrix protein-degrading cysteine protease expressed in osteoclasts J. Biol. Chem. 271 1996 2126 2132
20. D. Brömme, Z. Li, M. Barnes, and E. Mehler Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization Biochemistry 38 1999 2377 2385
21. B. Walker, J.F. Lynas, M.A. Meighan, and D. Brömme Evaluation of dipeptide α-keto-β-aldehydes as new inhibitors of cathepsin S Biochem. Biophys. Res. Commun. 275 2000 401 405
22. R.E. Higgs, M.D. Knierman, A.B. Freeman, L.M. Gelbert, S.T. Patil, and J.E. Hale Estimating the statistical significance of peptide identifications from shotgun proteomics experiments J. Proteome Res. 6 2007 1758 1767
23. E.J. Erlandsen, E. Randers, and J.H. Kristensen Reference intervals for serum cystatin C and serum creatinine in adults Clin. Chem. Lab. Med. 36 1998 393 397
24. D. Brömme, R. Rinne, and H. Kirschke Tight-binding inhibition of cathepsin S by cystatins Biomed. Biochim. Acta 50 1991 631 635
25. N. Cimerman, P.M. Brguljan, M. Krašovec, S. Šuš kovič, and J. Kos Circadian and concentration profile of cathepsin S in sera from healthy subjects and asthmatic patients Pflügers Arch. 442 2001 R204 R206
26. B. Turk, D. Turk, and G.S. Salvesen Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators Curr. Pharm. Biotechnol. 8 2002 1623 1637